Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2008-09-02
2008-09-02
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S192100, C424S230100, C435S235100, C435S320100
Reexamination Certificate
active
10886773
ABSTRACT:
The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising alphavirus replicon RNAs, wherein a first replicon RNA comprises nucleic acid encoding cytomegalovirus pp65 and IE1 protein or immunogenic fragments thereof, and a second replicon RNA comprises nucleic acid encoding cytomegalovirus gB protein or an immunogenic fragment thereof, and wherein each of the two replicon RNAs is contained within a separate alphavirus replicon particle.
REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 4708871 (1987-11-01), Geysen
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: 5521082 (1996-05-01), Lewis et al.
patent: 5639650 (1997-06-01), Johnston et al.
patent: 5643576 (1997-07-01), Johnston et al.
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5726022 (1998-03-01), Burmer
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5789245 (1998-08-01), Dubensky et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5811407 (1998-09-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky et al.
patent: 5827658 (1998-10-01), Liang et al.
patent: 5831016 (1998-11-01), Wang et al.
patent: 5843723 (1998-12-01), Dubensky et al.
patent: 5853719 (1998-12-01), Nair et al.
patent: 5958738 (1999-09-01), Lindermann et al.
patent: 5989553 (1999-11-01), Johnston et al.
patent: 6008035 (1999-12-01), Johnston et al.
patent: 6015686 (2000-01-01), Dubensky et al.
patent: 6015694 (2000-01-01), Dubensky et al.
patent: 6146874 (2000-11-01), Zolotukhin et al.
patent: 6156558 (2000-12-01), Johnston et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6194191 (2001-02-01), Zhang et al.
patent: 6197502 (2001-03-01), Renner et al.
patent: 6224879 (2001-05-01), Sjoberg et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6261570 (2001-07-01), Parker et al.
patent: 6267967 (2001-07-01), Johnston et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342226 (2002-01-01), Betbeder et al.
patent: 6342372 (2002-01-01), Dubensky et al.
patent: 6376236 (2002-04-01), Dubensky et al.
patent: 6391632 (2002-05-01), Dubensky et al.
patent: 6426196 (2002-07-01), Dubensky et al.
patent: 6448389 (2002-09-01), Gonczol et al.
patent: 6485958 (2002-11-01), Blanch et al.
patent: 6495143 (2002-12-01), Lee et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6531135 (2003-03-01), Johnston et al.
patent: 6541010 (2003-04-01), Johnston et al.
patent: 6583121 (2003-06-01), Johnston et al.
patent: 6767699 (2004-07-01), Polo et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: 6783939 (2004-08-01), Olmsted et al.
patent: 6844188 (2005-01-01), MacDonald et al.
patent: 7045335 (2006-05-01), Smith et al.
patent: 7267823 (2007-09-01), Hart et al.
patent: 2001/0016199 (2001-08-01), Johnston et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0034521 (2002-03-01), Lee et al.
patent: 2002/0102273 (2002-08-01), Grieve et al.
patent: 2002/0141975 (2002-10-01), Olmsted et al.
patent: 2002/0156251 (2002-10-01), Prieur et al.
patent: 2002/0164582 (2002-11-01), Hart et al.
patent: 2003/0021766 (2003-01-01), Vadjy et al.
patent: 2003/0091591 (2003-05-01), Xiong et al.
patent: 2003/0096397 (2003-05-01), Schlesinger et al.
patent: 2003/0119182 (2003-06-01), Smith et al.
patent: 2003/0120060 (2003-06-01), Gonczol et al.
patent: 2003/0148262 (2003-08-01), Polo et al.
patent: 2003/0152590 (2003-08-01), Hevey et al.
patent: 2003/0232036 (2003-12-01), Johnston et al.
patent: 2003/0232324 (2003-12-01), Polo et al.
patent: 2004/0008458 (2004-01-01), Kase et al.
patent: 2004/0009183 (2004-01-01), Lee et al.
patent: 2004/0009945 (2004-01-01), Lee et al.
patent: 2004/0029279 (2004-02-01), Kovacs et al.
patent: 2004/0030117 (2004-02-01), Johnston et al.
patent: 2004/0121466 (2004-06-01), Johnston et al.
patent: 2004/0146859 (2004-07-01), Hart et al.
patent: 2004/0166573 (2004-08-01), Smith et al.
patent: 2004/0208848 (2004-10-01), Smith et al.
patent: 2005/0031592 (2005-02-01), Doolan et al.
patent: 2005/0118251 (2005-06-01), Nagata et al.
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/07994 (1995-03-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 99/07834 (1999-02-01), None
patent: WO 99/08706 (1999-02-01), None
patent: WO 99/51263 (1999-10-01), None
patent: WO 00/39302 (2000-07-01), None
patent: WO 00/39318 (2000-07-01), None
patent: WO 00/61772 (2000-10-01), None
patent: WO 01/16343 (2001-03-01), None
patent: WO 02/003917 (2002-01-01), None
patent: WO 02/04493 (2002-01-01), None
patent: WO 02/20721 (2002-03-01), None
patent: WO 03/023026 (2003-03-01), None
patent: WO 03/083065 (2003-10-01), None
patent: WO 2004/055166 (2004-07-01), None
patent: WO 2004/055167 (2004-07-01), None
patent: WO 2004/085660 (2004-10-01), None
patent: WO 2005/007689 (2005-01-01), None
Tugizov et al., “Mutated Forms of Human Cytomegalovirus Glycoprotein B Are Impaired in Inducing Syncytium Formation,” Virology 209 (1995), pp. 580-591.
Vaz-Santiago, “Ex Vivo Stimulation and Expansion of both CD4 and CD8 T Cells from Peripheral Blood Mononuclear Cells of Human Cytomegalovirus-Seropositive Blood Donors by Using a Soluble Recombinant Chimeric Protein, IE1-pp65,” Journal of Virology, vol. 75, No. 17 (2001), pp. 7840-7847.
Caltenco-Serrano et al (Revista Latinoamericana de Microbiologia 43: 177-182, 2001).
Pugachev et al (Virology 212:587-594, 1995).
Elkington et al (Journal of virology 77:5226-5240, May 2003).
Davis et al. “Alphavirus Replicon Particles as Candidate HIV Vaccines”IUBMB Life53: 209-211 (2002).
Baric et al. “Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons”Journal of Virology76(6): 3023-3030 (2002).
Eiben et al. “Establishment of an HLA-A*0201 Human Papillomavirus Type 16 Tumor Model to Determine the Efficacy of Vaccination Strategies in HLA-A*0201 Transgenic Mice”Cancer Research62:5792-5799 (2002).
Eralp et al. “Doxorubicin and Paclitaxel Enhance the Antitumor Efficacy of Vaccines Directed Against HER 2
eu in a Murine Mammary Carcinoma Model”Breast Cancer Research6:R275-R283 (2004).
Lee et al. “Candidate Vaccine Against Botulinum Neurotoxin Serotype A Derived from a Venezeulan Equine Encephalitis Virus Vector System”Infection and Immunity69(9): 5709-5715 (2001).
Lee et al. “Immune Protection Against Staphylococcal Enterotoxin-Induced Toxic Shock by Vaccination with a Venezuelan Equine Encephalitis Virus Replicon”Journal of Infectious Diseases185: 1192-1196 (2002).
MacDonald et al. “Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus Pathogenesis”Journal of Virology74(2): 914-922 (2000).
Nelson et al. “Venezuelan Equine Encephalitis Replicon Immunization Overcomes Intrinsic Tolerance and Elicits Effective Anti-Tumor Immunity to the “self” Tumor Associated Antigen,neuin a Rat Mammary Tumor Model”Breast Cancer Research and Treatment63R: 1-15 (2003).
Pushko et al. “Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs Against Infection with Lassa and Ebola Viruses”Journal of Virology75(23): 11677-11685 (2001).
Schultz-Cherry et al. “Influenza Virus (A/HK/156/97) Hemagglutinin Expressed by an Alphavirus Replicon System Protects Chicken Against Lethal Infection with Hong Kong-Origin H5N1 Viruses”Virology278: 55-59 (2000).
Wang et al. “Alphavirus Replicon Particles Containing the Gene for HER2
eu Inhibit Breast Cancer Growth and Tumorigenesis”Breast Cancer Research7: R145-R155 (2005).
Velders et al. “Eradication of Established Tumors by Vaccination wi
Chulay Jeffrey D.
Dryga Sergey
Morris John S.
Olmsted Robert A.
Reap Elizabeth A.
Alpha Vax, Inc.
Mosher Mary E
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
Alpha virus-based cytomegalovirus vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha virus-based cytomegalovirus vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha virus-based cytomegalovirus vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3945362